A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Clinical trial NCT05952037 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05952037
- Sponsor
- BeOne Medicines
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-23
- Primary completion
- 2026-09-22
- Enrollment
- 114
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.